Targeting JWA for Cancer Therapy: Functions, Mechanisms and Drug Discovery

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Tumor heterogeneity limits the precision treatment of targeted drugs. It is important to find new tumor targets. JWA, also known as ADP ribosylation factor-like GTPase 6 interacting protein 5 (ARL6IP5, GenBank: AF070523, 1998), is a microtubule-associated protein and an environmental response gene. Substantial evidence shows that JWA is low expressed in a variety of malignancies and is correlated with overall survival. As a tumor suppressor, JWA inhibits tumor progression by suppressing multiple oncogenes or activating tumor suppressor genes. Low levels of JWA expression in tumors have been reported to be associated with multiple aspects of cancer progression, including angiogenesis, proliferation, apoptosis, metastasis, and chemotherapy resistance. In this review, we will discuss the structure and biological functions of JWA in tumors, examine the potential therapeutic strategies for targeting JWA and explore the directions for future investigation.
Funding Information
  • National Natural Science Foundation of China (81520108027, 81521004, 81973156 to JZ)
  • the Postgraduate Research & Practice Innovation Program of Jiangsu Province (JX10313791 to KD)

This publication has 140 references indexed in Scilit: